In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
All content for Talking Rheumatology Research is the property of British Society for Rheumatology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
Ep 48. Deciphering difficult-to-treat psoriatic arthritis
Talking Rheumatology Research
17 minutes
1 year ago
Ep 48. Deciphering difficult-to-treat psoriatic arthritis
Should there be distinct definitions for difficult-to-treat and complex-to-manage psoriatic arthritis? In this episode of Talking Rheumatology Research, Dr Fabian Proft and Dr Andre Ribeiro join Dr Ai Lyn Tan to discuss their work to define difficult-to-treat psoriatic arthritis, as part of GRAPPA's wider D2T-PsA project. Find out more: Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals ...
Talking Rheumatology Research
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
